Includes a first use checklist of Darzalex® SC.
Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more
María-Victoria Mateos of Hospital Universitario de Salamanca
21 February 2020 ASH 2019
María-Victoria Mateos of Hospital Universitario de Salamanca
21 February 2020 ASH 2019
Prof. María-Victoria Mateos presents 1-year updates from ALCYONE
An interactive video covering the key facts about the handling, preparation and administration of DARZALEX® SC
In this interactive video, Prof. Mateos gives an overview of the DARZALEX® SC PAVO, COLUMBA and PLEIADES studies.
Access downloadable patient materials to help your patients and their caregivers on their journey with MM treatment
AL: amyloid light chain
IRR: infusion-related reaction
MM: multiple myeloma
MOA: mode of action
Rd: lenalidomide, dexamethasone
SC: subcutaneous
VCd: Velcade®, cyclophosphamide, dexamethasone
Vd: Velcade®, dexamethasone
VMP: Velcade®, melphalan, prednisone
VTd: Velcade®, thalidomide, dexamethasone
Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Darzalex®, veja aqui